We have located links that may give you full text access.
Clinical Trial
Journal Article
Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.
European Journal of Nuclear Medicine and Molecular Imaging 2017 Februrary
PURPOSE: Therapy with the alpha-emitter radium-223 chloride ((223)Ra) is an innovative therapeutic option in patients with metastasized, castration-resistant prostate cancer. However, radiotherapy can lead to hematopoietic toxicity. The aim of this study was to determine if (223)Ra therapy induces an impairment of cellular antimicrobial immune responses.
METHODS: In 11 patients receiving (223)Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy.
RESULTS: Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment.
CONCLUSIONS: The results argue against an impairment of lymphocyte function after (223)Ra therapy. Thus, immune responses against pathogens should remain unaffected.
METHODS: In 11 patients receiving (223)Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy.
RESULTS: Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment.
CONCLUSIONS: The results argue against an impairment of lymphocyte function after (223)Ra therapy. Thus, immune responses against pathogens should remain unaffected.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app